

## LIST OF TABLES

	Page
Table I	10
Table II	10
Table 1.1	22
Table 1.2	23
Table 1.3	23
Table 1.4	24
Table 1.5	25
Table 1.6	26
Table 1.7	26
Table 1.8	27
Table 1.9	28
Table 1.10	28
Table 1.11	30
Table 1.12	31
Table 1.13	32
Table 1.14	33
Table 2.1	39
Table 2.2	40
Table 2.3	40
Table 2.4	41
Table 2.5	42
Table 2.6	42
Table 2.7	43
Table 2.8	45
Table 2.9	46
Table 2.10	47
Table 2.11	48
Table 2.12	49



	Page	
Table 2.13	Use of PET scan among patients who had cancer staging by cancer stage (N=8,020)	49
Table 2.14	Histological type of invasive breast cancer (N=16,996)	53
Table 2.15	Grading, multifocality and multicentricity of invasive breast cancer (N=16,996)	54
Table 2.16	Biological characteristics of invasive breast cancer (N=16,996)	55
Table 2.17	Biological subtypes of invasive tumours by cancer stage (N=15,853)	56
Table 2.18	Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=2,617)	57
Table 2.19	Biological characteristics of in situ breast cancer (N=2,617)	58
Table 2.20	Use of surgery for patients with invasive cancer	60
Table 2.21	Use of surgery for patients with in situ cancer	61
Table 2.22	Type of breast surgery by age group (N=19,320)	62
Table 2.23	Type of breast surgery by invasive tumour size (cm) (N=15,405)	62
Table 2.24	Type of breast surgery by cancer stage (N=19,044)	62
Table 2.25	Type of breast surgery by type of medical service (N=18,937)	63
Table 2.26	Type of nodal surgery by clinical nodal status (N=18,388)	63
Table 2.27	Type of nodal surgery for invasive cancer by cancer stage (N=16,194)	64
Table 2.28	Distribution of tumour size (cm) in invasive cancer with negative or positive nodal status (N=14,231)	64
Table 2.29	Number of positive nodes by type of nodal surgery (N=17,911)	65
Table 2.30	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=7,355)	67
Table 2.31	Chemotherapy treatment by cancer stage (N=16,713)	68
Table 2.32	Use of chemotherapy by age group and cancer stage at diagnosis (N=16,418)	68
Table 2.33	Forms of endocrine therapy by age group (N=12,422)	82
Table 2.34	Type of targeted therapy drugs used (N=2,795)	82
Table 2.35	Number of treatment modalities by cancer stage (N=19,309)	83
Table 2.36	Follow-up of patients (N=18,155)	85
Table 2.37	Locoregional recurrence by type of surgery received and cancer stage at diagnosis	86
Table 2.38	Sites involved in locoregional recurrence (N=627)	86
Table 2.39	Organs involved in distant recurrence (N=750)	86
Table 2.40	Time for organ specific metastasis and distribution of the biological subtypes of patients	87
Table 2.41	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=15,950)	87
Table 2.42	Characteristics of breast cancer-specific deaths (N=232)	88
Table 3.1	Mean scores on cancer-specific scale	94
Table 3.2	Psychosocial impact of breast cancer	97

## LIST OF FIGURES

	Page
Figure I	6
Figure 1	6
Figure 1.1	15
Figure 1.2	16
Figure 1.3	17
Figure 1.4	17
Figure 1.5	18
Figure 1.6	19
Figure 1.7	19
Figure 1.8	21
Figure 1.9	21
Figure 1.10	21
Figure 1.11	29
Figure 2.1	39
Figure 2.2	41
Figure 2.3	44
Figure 2.4	46
Figure 2.5	50
Figure 2.6	51
Figure 2.7	52
Figure 2.8	52
Figure 2.9	66
Figure 2.10	66
Figure 2.11	69
Figure 2.12	69
Figure 2.13	70
Figure 2.14	70
Figure 2.15	71
Figure 2.16	73
Figure 2.17	73



Figure 2.18	Type of third generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,718)	74
Figure 2.19	Type of HER2 regimens used in adjuvant setting (N=825)	74
Figure 2.20	Type of chemotherapy regimens used by biological subtype in adjuvant setting (N=8,269)	75
Figure 2.21	Type of chemotherapy regimens used by cancer stage in adjuvant setting (N=8,418)	77
Figure 2.22	Type of chemotherapy regimens used by biological subtype in palliative setting (N=283)	78
Figure 2.23	Use of endocrine therapy by cancer stage (N=19,309)	81
Figure 2.24	Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=3,480)	83
Figure 2.25	Type of complementary and alternative therapies used (N=7,201)	84
Figure 3.1	Level of physical discomfort after surgery (N=17,829)	91
Figure 3.2	Level of physical discomfort after radiotherapy (N=10,490)	91
Figure 3.3	Level of physical discomfort after chemotherapy (N=9,149)	92
Figure 3.4	Level of physical discomfort after endocrine therapy (N=11,300)	92
Figure 3.5	Level of physical discomfort after targeted therapy (N=2,303)	93
Figure 3.6	Correlations between symptom scales and age	95
Figure 3.7	Correlations between functional scales and age	95
Figure 3.8	Correlations between emotional scales and age	98